2016_Head & Neck COURSE BOOK

Hypoxia-classification 15-gene hypoxia classifier

Effect of hypoxic modification Unclassified patients (n=323)

Events All 0 25 50 75 100 Loco-regional control (%) Placebo Nimorazole HR=0.71 (0.53 to 0.95) 96 156 83 167

Nimorazole

50%

Placebo

36%

P=0.02

0 12 24 36 48 60 Time after treatment (months)

Less hypoxic tumours

More hypoxic tumours

Events All 0 25 50 75 100 Loco-regional control (%) Placebo Nimorazole HR=0.85 (0.58 to 1.23) 62 113 50 96

Events All 0 25 50 75 100 Loco-regional control (%) Placebo Nimorazole HR=0.46 (0.29 to 0.75) 34 43 33 71

(n=114)

(n=209)

Nimorazole

Nimorazole

49%

50%

44%

Placebo

Placebo

18%

P=0.001

P=0.39

0 12 24 36 48 60 Time after treatment (months)

0 12 24 36 48 60 Time after treatment (months)

-Toustrup K et al, Radiother Oncol; 102; 122-129, 2012